Novo Nordisk A/S: Transaction in Own Shares

BAGSVAERD, DENMARK, Nov 09 (MARKET WIRE) --
On 7 August 2009 Novo Nordisk initiated its share repurchase programme in
accordance with the provisions of the European Commission's regulation no
2273/2003 of 22 December 2003, also referred to as the Safe Harbour
rules.

On 7 August 2009 Novo Nordisk initiated its share repurchase
programme in accordance with the provisions of the European Commission's
regulation no 2273/2003 of 22 December 2003, also referred to as the Safe
Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount
up to DKK 2.4 billion in the period from 10 August 2009 to 18 December
2009.

Since the announcement as of 2 November 2009, the following transactions
have been made under the programme:

Number of shares Average Transaction
purchase price value, DKK
Accumulated, last
announcement 4,669,099 1,490,518,113
2 November 2009 75,000 315.9100 23,693,250
3 November 2009 75,000 316.9650 23,772,375
4 November 2009 75,000 323.8510 24,288,825
5 November 2009 80,000 324.2290 25,938,320
6 November 2009 115,000 320.5820 36,866,930
Accumulated under the
programme 5,089,099 1,625,077,813

Transactions related to Novo Nordisk's incentive programmes have
resulted in a net sale by Novo Nordisk of 57,850 B shares in the period
from 2 November 2009 to 6 November 2009. The shares in these transactions
were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of
29,838,977 treasury shares, corresponding to 4.8% of the share capital.
The total amount of shares in the company is 620,000,000 including
treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes care.
In addition, Novo Nordisk has a leading position within areas such as
haemostasis management, growth hormone therapy and hormone replacement
therapy. Novo Nordisk manufactures and markets pharmaceutical products
and services that make a significant difference to patients, the medical
profession and society. With headquarters in Denmark, Novo Nordisk
employs more than 29,000 employees in 81 countries, and markets its
products in 179 countries. Novo Nordisk's B shares are listed on the
stock exchanges in Copenhagen and London. Its ADRs are listed on the New
York Stock Exchange under the symbol 'NVO'. For more information,
visit
novonordisk.com.

Further information:

Media: Investors:

Elin K Hansen Mads Veggerby Lausten
Tel: (+45) 4442 3450 Tel: (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com

Kasper Roseeuw Poulsen
Tel: (+45) 4442 4471
krop@novonordisk.com

In North America: In North America:
Sean Clements Hans Rommer
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com hrmm@novonordisk.com

Company Announcement no 67 / 2009

This announcement was originally
distributed by Hugin. The issuer is solely responsible for the content of
this announcement.

Copyright Copyright Hugin AS 2009. All rights
reserved.

Copyright 2009, Market Wire, All rights reserved.

-0-